Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study (2017)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1097/IGC.0000000000000836
- Subjects: NEOPLASIAS OVARIANAS; ANTINEOPLÁSICOS; RESULTADO DE TRATAMENTO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2017
- Source:
- Título: International journal of gynecological cancer
- ISSN: 1048-891X
- Volume/Número/Paginação/Ano: v. 27, n. 1, p. 50-58, 2017
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
OZA, Amit M. e HEGG, Roberto. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, v. 27, n. 1, p. 50-58, 2017Tradução . . Disponível em: https://doi.org/10.1097/IGC.0000000000000836. Acesso em: 24 jan. 2026. -
APA
Oza, A. M., & Hegg, R. (2017). Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, 27( 1), 50-58. doi:10.1097/IGC.0000000000000836 -
NLM
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1097/IGC.0000000000000836 -
Vancouver
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1097/IGC.0000000000000836 - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
Informações sobre o DOI: 10.1097/IGC.0000000000000836 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
